![[personal profile]](https://www.dreamwidth.org/img/silk/identity/user.png){kind=small}
SARS-CoV-2 vaccine and increased myocarditis mortality risk: A population based comparative study in Japan.
ABSTRACT Objective: To investigate the association between SARS-CoV-2 vaccination and myocarditis death Design: Population based comparative mortality study Setting: Japan Participants: Vaccinated population was 99 834 543 individuals aged 12 years and older who have been received SARS-CoV-2 vaccine once or twice by 14 February 2022. Reference population was defined persons aged 10 years and older from 2017 to 2019. Main outcome measures: The primary outcome was myocarditis death, defined as the case with "myocarditis" for cause of death and with onset 28 days or less after vaccination disclosed on 5 August 2022. Myocarditis mortality rate ratio (MMRR) of the SARS-CoV-2 vaccinated to the reference population by 10-year age group and standardised mortality ratio (SMR) were calculated. Mortality odds ratios (MORs) by 10-year age group were also calculated for supplementary analysis. Healthy vaccine effect-adjusted MMRRs (adMMRRs) or adjusted SMR (adSMR) were calculated by dividing MMRRs or SMR by 0.24 respectively. Results: Number of myocarditis death which met the inclusion criteria were 38 cases. MMRR (95% confidence interval) was 4.03 (0.77 to 13.60) in 20s, 6.69 (2.24 to 16.71) in 30s, 3.89 (1.48 to 8.64) in 40s, respectively. SMR of myocarditis was 2.01 (1.44 to 2.80) for overall vaccinated population, 1.65 (1.07 to 2.55) for those 60 years or older. Estimated adMMRRs and adSMR were about 4 times higher than the MMRRs and SMR. Pooled MOR for myocarditis were 205.60 (133.52 to 311.94). Conclusion: SARS-CoV-2 vaccination was associated with higher risk of myocarditis death, not only in young adults but also in all age groups including the elderly. Considering healthy vaccinee effect, the risk may be 4 times or higher than the apparent risk of myocarditis death. Underreporting should also be considered. Based on this study, risk of myocarditis following SARS-CoV-2 vaccination may be more serious than that reported previously.
Только надо помнить, что от самого ковида эти риски еще выше.
ABSTRACT Objective: To investigate the association between SARS-CoV-2 vaccination and myocarditis death Design: Population based comparative mortality study Setting: Japan Participants: Vaccinated population was 99 834 543 individuals aged 12 years and older who have been received SARS-CoV-2 vaccine once or twice by 14 February 2022. Reference population was defined persons aged 10 years and older from 2017 to 2019. Main outcome measures: The primary outcome was myocarditis death, defined as the case with "myocarditis" for cause of death and with onset 28 days or less after vaccination disclosed on 5 August 2022. Myocarditis mortality rate ratio (MMRR) of the SARS-CoV-2 vaccinated to the reference population by 10-year age group and standardised mortality ratio (SMR) were calculated. Mortality odds ratios (MORs) by 10-year age group were also calculated for supplementary analysis. Healthy vaccine effect-adjusted MMRRs (adMMRRs) or adjusted SMR (adSMR) were calculated by dividing MMRRs or SMR by 0.24 respectively. Results: Number of myocarditis death which met the inclusion criteria were 38 cases. MMRR (95% confidence interval) was 4.03 (0.77 to 13.60) in 20s, 6.69 (2.24 to 16.71) in 30s, 3.89 (1.48 to 8.64) in 40s, respectively. SMR of myocarditis was 2.01 (1.44 to 2.80) for overall vaccinated population, 1.65 (1.07 to 2.55) for those 60 years or older. Estimated adMMRRs and adSMR were about 4 times higher than the MMRRs and SMR. Pooled MOR for myocarditis were 205.60 (133.52 to 311.94). Conclusion: SARS-CoV-2 vaccination was associated with higher risk of myocarditis death, not only in young adults but also in all age groups including the elderly. Considering healthy vaccinee effect, the risk may be 4 times or higher than the apparent risk of myocarditis death. Underreporting should also be considered. Based on this study, risk of myocarditis following SARS-CoV-2 vaccination may be more serious than that reported previously.
Только надо помнить, что от самого ковида эти риски еще выше.
![[community profile]](https://www.dreamwidth.org/img/silk/identity/community.png){kind=small}